Copyright
©The Author(s) 2004.
World J Gastroenterol. Aug 15, 2004; 10(16): 2379-2382
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Table 5 Incidence of adverse events (n, %)
| DA-9601 180 mg | Cetraxate 600 mg | |
| Gastrointestinal | ||
| Dyspepsia | 2 (1.08) | 0 |
| Nausea | 2 (1.08) | 0 |
| Diarrhea | 2 (1.08) | 0 |
| Heartburn | 1 (0.54) | 1 (0.54) |
| Abdominal pain | 1 (0.54) | 1 (0.54) |
| Acid reflux | 0 | 1 (0.54) |
| Vomiting | 1 (0.54) | 1 (0.54) |
| CNS and ANS | ||
| Dizziness | 1 (0.54) | 0 |
| Headache | 1 (0.54) | 1 (0.54) |
| Skin | ||
| Itching | 1 (0.54) | 1 (0.54) |
| Skin redness | 1 (0.54) | 1 (0.54) |
| Facial edema | 0 | 1 (0.54) |
| Liver | ||
| sGPT elevation | 1 (0.54) | 1 (0.54) |
| sGOT elevation | 0 | 1 (0.54) |
| Bilirubin elevation | 0 | 1 (0.54) |
| Total | 14 (7.53) | 11 (5.91) |
- Citation: Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial. World J Gastroenterol 2004; 10(16): 2379-2382
- URL: https://www.wjgnet.com/1007-9327/full/v10/i16/2379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i16.2379